Xiao Chai Hu Tang inhibits CVB1 virus infection of CCFS-1 cells through the induction of Type I interferon expression

International Immunopharmacology

Volumn 6, Issue 6, 2006, Pages 1003-1012

  Cheng, Pei Wen ^a   Ng, Lean Teik ^b   Lin, Chun Ching ^a  

^a KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

^b TAJEN UNIVERSITY   (Taiwan)

Author keywords

Antiviral activity; Coxsackie B virus type 1 (CVB1); Interferon alpha beta (IFN ); Xiao Chai Hu Tang (XCHT)

Indexed keywords

ALPHA INTERFERON; BETA INTERFERON; HERBACEOUS AGENT; XIAO CHAI HU TANG;

ANTIVIRAL ACTIVITY; ARTICLE; BACTERIAL INFECTION; CELL GROWTH; CELL MEDIATED CYTOTOXICITY; CELL VIABILITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; COXSACKIE VIRUS B; COXSACKIE VIRUS INFECTION; CYTOPATHOGENIC EFFECT; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; FIBROBLAST CULTURE; HUMAN; HUMAN CELL; IC 50; INFECTION CONTROL; NEWBORN; NONHUMAN; PREPUCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; VIRUS INHIBITION; VIRUS REPLICATION;

ANTIBODIES, MONOCLONAL; ANTIVIRAL AGENTS; CELL LINE; CELL SURVIVAL; CYTOPATHOGENIC EFFECT, VIRAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUGS, CHINESE HERBAL; ENTEROVIRUS B, HUMAN; FIBROBLASTS; HUMANS; INHIBITORY CONCENTRATION 50; INTERFERON TYPE I; INTERFERON-ALPHA; INTERFERON-BETA; RIBAVIRIN; TIME FACTORS; VIRUS REPLICATION;

EID: 33646492195     PISSN: 15675769     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.intimp.2006.01.011     Document Type: Article

References (68)

1. Galbraith D.N., Nairn C., and Clements G.B. Evidence for enteroviral persistence in humans. J Gen Virol 78 Pt 2 (1997) 307-312
2. Muir P., Nicholson F., Illavia S.J., McNeil T.S., Ajetunmobi J.F., Dunn H., et al. Serological and molecular evidence of enterovirus infection in patients with end-stage dilated cardiomyopathy. Heart 76 (1996) 243-249
3. Ramsingh A.I., Chapman N., and Tracy S. Coxsackieviruses and diabetes. Bioessays 19 (1997) 793-800
4. Kandolf R., Klingel K., Zell R., Selinka H.C., Raab U., Schneider-Brachert W., et al. Molecular pathogenesis of enterovirus-induced myocarditis: virus persistence and chronic inflammation. Intervirology 35 (1993) 140-151
5. Toniolo A., Onodera T., Jordan G., Yoon J.W., and Notkins A.L. Virus-induced diabetes mellitus. Glucose abnormalities produced in mice by the six members of the Coxsackie B virus group. Diabetes 31 (1982) 496-499
6. Minnich L.L., and Ray C.G. Variable susceptibility of mice to group B coxsackievirus infections. J Clin Microbiol 11 (1980) 73-75
7. Yokota S., Yokosawa N., Kubota T., Suzutani T., Yoshida I., Miura S., et al. Herpes simplex virus type 1 suppresses the interferon signaling pathway by inhibiting phosphorylation of STATs and janus kinases during an early infection stage. Virology 286 (2001) 119-124
8. Chebath J., Benech P., Revel M., and Vigneron M. Constitutive expression of (2′-5′) oligo A synthetase confers resistance to picornavirus infection. Nature 330 (1987) 587-588
9. Meurs E.F., Watanabe Y., Kadereit S., Barber G.N., Katze M.G., Chong K., et al. Constitutive expression of human double-stranded RNA-activated p68 kinase in murine cells mediates phosphorylation of eukaryotic initiation factor 2 and partial resistance to encephalomyocarditis virus growth. J Virol 66 (1992) 5805-5814
10. Stark G.R., Kerr I.M., Williams B.R., Silverman R.H., and Schreiber R.D. How cells respond to interferons. Annu Rev Biochem 67 (1998) 227-264
11. Heim A., Canu A., Kirschner P., Simon T., Mall G., Hofschneider P.H., et al. Synergistic interaction of interferon-beta and interferon-gamma in coxsackievirus B3-infected carrier cultures of human myocardial fibroblasts. J Infect Dis 166 (1992) 958-965
12. Matsumori A., Tomioka N., and Kawai C. Protective effect of recombinant alpha interferon on coxsackievirus B3 myocarditis in mice. Am Heart J 115 (1988) 1229-1232
13. Okita K., Li Q., Murakamio T., and Takahashi M. Anti-growth effects with components of sho-saiko-to (TJ-9) on cultured human hepatoma cells. Eur J Cancer Prev 2 (1993) 169-175
14. Tajiri H., Kozaiwa K., Ozaki Y., Miki K., Shimuzu K., and Okada S. Effect of sho-saiko-to (xiao-chai-hu-tang) on HBeAg clearance in children with chronic hepatitis B virus infection and with sustained liver disease. Am J Chin Med 19 (1991) 121-129
15. Yamashiki M., Kosaka Y., Nishimura A., Takase K., and Ichida F. Efficacy of a herbal medicine sho-saiko-to on the improvement of impaired cytokine production of peripheral blood mononuclear cells in patients with chronic viral hepatitis. J Clin Lab Immunol 37 (1992) 111-121
16. Sakaida I., Matsumura Y., Akiyama S., Hayashi K., Ishige A., and Okita K. Herbal medicine sho-saiko-to (TJ-9) prevents liver fibrosis and enzyme-altered lesions in rat liver cirrhosis induced by a choline-deficient l-amino acid-defined diet. J Hepatol 28 (1998) 298-306
17. Shimizu I., Ma Y.R., Mizobuchi Y., Liu F., Miura T., Nakai Y., et al. Effects of sho-saiko-to, a Japanese herbal medicine, on hepatic fibrosis in rats. Hepatology 29 (1999) 149-160
18. Hirayama C., Okumura M., Tanikawa K., Yano M., Mizuta M., and Ogawa N. A multicenter randomized controlled clinical trial of sho-saiko-to in chronic active hepatitis. Gastroenterol Jpn 24 (1989) 715-719
19. Yano H., Mizoguchi A., Fukuda K., Haramaki M., Ogasawara S., Momosaki S., et al. The herbal medicine sho-saiko-to inhibits proliferation of cancer cell lines by inducing apoptosis and arrest at the G0/G1 phase. Cancer Res 54 (1994) 448-454
20. Sakaguchi S., Tsutsumi E., and Yokota K. Preventive effects of a traditional Chinese medicine (sho-saiko-to) against oxygen toxicity and membrane damage during endotoxemia. Biol Pharm Bull 16 (1993) 782-786
21. Egashira T., Takayama F., Yamanaka Y., and Komatsu Y. Monitoring of radical scavenging activity of peroral administration of the Kampo medicine sho-saiko-to in rats. Jpn J Pharmacol 80 (1999) 379-382
22. Yamashiki M., Nishimura A., Nobori T., Nakabayashi S., Takagi T., Inoue K., et al. In vitro effects of sho-saiko-to on production of granulocyte colony-stimulating factor by mononuclear cells from patients with chronic hepatitis C. Int J Immunopharmacol 19 (1997) 381-385
23. Yamashiki M., Nishimura A., Suzuki H., Sakaguchi S., and Kosaka Y. Effects of the Japanese herbal medicine "sho-saiko-to" (TJ-9) on in vitro interleukin-10 production by peripheral blood mononuclear cells of patients with chronic hepatitis C. Hepatology 25 (1997) 1390-1397
24. Fujiwara K., Mochida S., Nagoshi S., Iijima O., Matsuzaki Y., Takeda S., et al. Regulation of hepatic macrophage function by oral administration of xiao-chai-hu-tang (sho-saiko-to, TJ-9) in rats. J Ethnopharmacol 46 (1995) 107-114
25. Kayano K., Sakaida I., Uchida K., and Okita K. Inhibitory effects of the herbal medicine sho-saiko-to (TJ-9) on cell proliferation and procollagen gene expressions in cultured rat hepatic stellate cells. J Hepatol 29 (1998) 642-649
26. Liu W., Kato M., Akhand A.A., Hayakawa A., Takemura M., Yoshida S., et al. The herbal medicine sho-saiko-to inhibits the growth of malignant melanoma cells by upregulating Fas-mediated apoptosis and arresting cell cycle through downregulation of cyclin dependent kinases. Int J Oncol 12 (1998) 1321-1326
27. Huang X.X., Yamashiki M., Nakatani K., Nobori T., and Mase A. Semi-quantitative analysis of cytokine mRNA expression induced by the herbal medicine sho-saiko-to (TJ-9) using a Gel Doc system. J Clin Lab Anal 15 (2001) 199-209
28. Matsuura K., Kawakita T., Nakai S., Saito Y., Suzuki A., and Nomoto K. Role of B-lymphocytes in the immunopharmacological effects of a traditional Chinese medicine, xiao-chai-hu-tang (sho-saiko-to). Int J Immunopharmacol 15 (1993) 237-243
29. Kakumu S., Yoshioka K., Wakita T., and Ishikawa T. Effects of TJ-9 sho-saiko-to (kampo medicine) on interferon gamma and antibody production specific for hepatitis B virus antigen in patients with type B chronic hepatitis. Int J Immunopharmacol 13 (1991) 141-146
30. Ono K., Nakane H., Fukushima M., Chermann J.C., and Barre-Sinoussi F. Differential inhibition of the activities of reverse transcriptase and various cellular DNA polymerases by a traditional Kampo drug, sho-saiko-to. Biomed Pharmacother 44 (1990) 13-16
31. Yen M.H., Lin C.C., Chuang C.H., and Liu S.Y. Evaluation of root quality of Bupleurum species by TLC scanner and the liver protective effects of "xiao-chai-hu-tang" prepared using three different Bupleurum species. J Ethnopharmacol 34 (1991) 155-165
32. Chiang L.C., Chiang W., Chang S.F., and Chen H.Y. Spontaneous production of growth factors for human lymphocytes from a human papillomavirus type 18-contained foreskin fibroblast cell line. Gaoxiong Yi Xue Ke Xue Za Zhi 8 (1992) 121-126
33. Chiang L.C., Chiang W., Chang M.Y., Ng L.T., and Lin C.C. Antiviral activity of Plantago major extracts and related compounds in vitro. Antiviral Res 55 (2002) 53-62
34. Oka H., Yamamoto S., Kuroki T., Harihara S., Marumo T., Kim S.R., et al. Prospective study of chemoprevention of hepatocellular carcinoma with sho-saiko-to (TJ-9). Cancer 76 (1995) 743-749
35. Yamashiki M., Nishimura A., Nomoto M., Suzuki H., and Kosaka Y. Herbal medicine "sho-saiko-to" induces tumour necrosis factor-alpha and granulocyte colony-stimulating factor in vitro in peripheral blood mononuclear cells of patients with hepatocellular carcinoma. J Gastroenterol Hepatol 11 (1996) 137-142
36. Yamashiki M., Nishimura A., Huang X.X., Nobori T., Sakaguchi S., and Suzuki H. Effects of the Japanese herbal medicine "sho-saiko-to" (TJ-9) on interleukin-12 production in patients with HCV-positive liver cirrhosis. Dev Immunol 7 (1999) 17-22
37. Yonekura K., Kawakita T., Mitsuyama M., Miura O., Yumioka E., Suzuki A., et al. Induction of colony-stimulating factor(s) after administration of a traditional Chinese medicine, xiao-chai-hu-tang (Japanese name: sho-saiko-to). Immunopharmacol Immunotoxicol 12 (1990) 647-667
38. Kaneko M., Kawakita T., Tauchi Y., Saito Y., Suzuki A., and Nomoto K. Augmentation of NK activity after oral administration of a traditional Chinese medicine, xiao-chai-hu-tang (sho-saiko-to). Immunopharmacol Immunotoxicol 16 (1994) 41-53
39. Yamaoka Y., Kawakita T., Kaneko M., and Nomoto K. A polysaccharide fraction of sho-saiko-to active in augmentation of natural killer activity by oral administration. Biol Pharm Bull 8 (1995) 846-849
40. Chiang L.C., Ng L.T., Liu L.T., Shieh D.E., and Lin C.C. Cytotoxicity and anti-hepatitis B virus activities of saikosaponins from Bupleurum species. Planta Med 69 (2003) 705-709
41. Hsu Y.L., Kuo P.L., and Lin C.C. The proliferative inhibition and apoptotic mechanism of saikosaponin D in human non-small cell lung cancer A549 cells. Life Sci 75 (2004) 1231-1242
42. Bermejo P., Abad M.J., Diaz A.M., Fernandez L., Santos J.D., Sanchez S., et al. Antiviral activity of seven iridoids, three saikosaponins and one phenylpropanoid glycoside extracted from Bupleurum rigidum and Scrophularia scorodonia. Plant Med 68 (2002) 106-110
43. Ohtake N., Nakai Y., Yamamoto M., Sakakibara I., Takeda S., Amagaya S., et al. Separation and isolation methods for analysis of the active principles of sho-saiko-to (SST) oriental medicine. J Chormatogr B 812 (2004) 135-148
44. Ohtake N., Yamamoto M., Takeda S., Aburada M., Ishige A., Watanabe K., et al. The herbal medicine Sho-saiko-to selectively inhibits CD8+ T-cell proliferation. Eur J Pharmacol 507 (2005) 301-310
45. Shi Y., Shi R.B., Liu B., Lu Y.R., and Du L.J. Isolation and elucidation of chemical constituents with antiviral action from yinqiaosan on influenza virus. Zhongguo Zhong Yao Za Zhi 28 (2003) 43-47
46. Taira Z., Yabe K., Hamaguchi Y., Hirayama K., Kishimoto M., Ishida S., et al. Effects Sho-saiko-to extract and its components, baicalin, baicalein, glycyrrhizin and glycyrrhetic acid, on pharmacokinetic behavior of salicylamide in carbon tetrachloride intoxicated rats. Food Chem Toxicol 42 (2004) 803-807
47. Kroes B.H., Beukelman C.J., van den Berg A.J., Wolbink G.J., van Dijk H., and Labadie R.P. Inhibition of human complement by beta-glycyrrhetinic acid. Immunology 90 (1997) 115-120
48. Francischetti I.M., Monteiro R.Q., and Guimaraes J.A. Identification of glycyrrhizin as a thrombin inhibitor. Biochem Biophys Res Commun 235 (1997) 259-263
49. Zani F., Cuzzoni M.T., Daglia M., Benvenuti S., Vampa G., and Mazza P. Inhibition of mutagenicity in Salmonella typhimurium by Glycyrrhiza glabra extract, glycyrrhizinic acid, 18 alpha- and 18 beta-glycyrrhetinic acids. Planta Med 59 (1993) 502-507
50. Ito M., Nakashima H., Baba M., Pauwels R., De Clercq E., Shigeta S., et al. Inhibitory effect of glycyrrhizin on the in vitro infectivity and cytopathic activity of the human immunodeficiency virus [HIV (HTLV-III/LAV)]. Antiviral Res 7 (1987) 127-137
51. Lin C.C., and Shieh D.E. The anti-inflammatory activity of Scutellaria rivularis extracts and its active components, baicalin, baicalein and wogonin. Am J Chin Med 24 (1996) 31-36
52. Chou T.C., Chang L.P., Li C.Y., Wong C.S., and Yang S.P. The anti-inflammatory and analgesic effects of baicalin in carrageenan-evoked thermal hyperalgesia. Anesth Analg 97 (2003) 1724-1729
53. Ikemoto S., Sugimura K., Yoshida N., Yasumoto R., Wada S., Yamamoto K., et al. Antitumor effects of Scutellariae radix and its components baicalein, baicalin, and wogonin on bladder cancer cell lines. Urology 55 (2000) 951-955
54. Wu J.A., Attele A.S., Zhang L., and Yuan C.S. Anti-HIV activity of medicinal herbs: usage and potential development. Am J Chin Med 29 (2001) 69-81
55. Kimura Y., Matsushita N., and Okuda H. Effects of baicalein isolated from Scutellaria baicalensis on interleukin 1 beta-and tumor necrosis factor alpha-induced adhesion molecule expression in cultured human umbilical vein endothelial cells. J Ethnopharmacol 57 (1997) 63-67
56. Galgon T., Wohlrab W., and Drager B. Betulinic acid induces apoptosis in skin cancer cells and differentiation in normal human keratinocytes. Exp Dermatol 14 (2005) 735-743
57. Kim E.C., Min J.K., Kim T.Y., Lee S.J., Yang H.O., Han S., et al. 6-Gingerol, a pungent ingredient of ginger, inhibits angiogenesis in vitro and in vivo. Biochem Biophys Res Commun 335 (2005) 300-308
58. Young H.Y., Luo Y.L., Cheng H.Y., Hsieh W.C., Liao J.C., and Peng W.H. Analgesic and anti-inflammatory activities of 6-gingerol. J Ethnopharmacol 96 (2005) 207-210
59. Surh Y.J., Park K.K., Chun K.S., Lee L.J., Lee E., and Lee S.S. Anti-tumor promoting activities of selected pungent phenolic substances present in ginger. J Environ Pathol Toxicol Oncol 18 (1999) 131-139
60. Wang C.C., Chen L.G., Lee L.T., and Yang L.L. Effects of 6-gingerol, an antioxidnat from ginger, on inducing apoptosis in human leukemic HL-60 cells. In Vivo 17 (2003) 641-645
61. Lee H.U., Bae E.A., Han M.J., Kim N.J., and KIm D.H. Hepatoprotective effect of ginsenoside Rb1 and compound K on tert-butyl hydroperoxide-induced liver injury. Liver Int 25 (2005) 1069-1073
62. Wang W.X., Wang W., and Chen K.J. Protective effect and mechanism of ginsenosides on central nervous system of animals. Zhongguo Zhong Xi Yi Jie He Za Zhi 25 (2005) 89-93
63. Cheng Y., Shen L.H., and Zhang J.T. Anti-amnestic and anti-aging effects of ginsenoside Rg1 and Rb1 and its mechanism of action. Acta Pharmacol Sin 26 (2005) 143-149
64. Rivera E., Ekholm Pettersson F., Inganas M., Paulie S., and Gronvik K.O. The Rb1 fraction of ginseng elicits a balanced Th1 and Th2 immune response. Vaccine 23 (2005) 5411-5419
65. Pfeffer L.M., Dinarello C.A., Herberman R.B., Williams B.R., Borden E.C., Bordens R., et al. Biological properties of recombinant alpha-interferons: 40th anniversary of the discovery of interferons. Cancer Res 58 (1998) 2489-2499
66. Rodriguez J.E., Loepfe T.R., and Swack N.S. Beta interferon production in primed and unprimed cells infected with human cytomegalovirus. Arch Virol 94 (1987) 177-189
67. Guidotti L.G., and Chisari F.V. Noncytolytic control of viral infections by the innate and adaptive immune response. Annu Rev Immunol 19 (2001) 65-91
68. Deonarain R., Cerullo D., Fuse K., Liu P.P., and Fish E.N. Protective role for interferon-beta in coxsackievirus B3 infection. Circulation 110 (2004) 3540-3543